What new Alzheimer’s drug target reduces plaques?

New enzyme target for Alzheimer’s treatment

Scientists at Indiana University School of Medicine identified a potential enzyme target linked to Alzheimer’s pathology, pointing to a possible alternative drug-development route. The research is focused on biological mechanisms that influence the buildup of amyloid plaques, one of the best-known hallmarks of the disease.

The key idea is that blocking or modulating the activity of a specific enzyme could shift the brain’s chemistry in a way that reduces plaque accumulation. In Alzheimer’s research, even small changes in plaque burden can matter because amyloid deposition is tightly tied to downstream neuroinflammation and neuronal dysfunction over time.

Why this matters

• Adds a new pathway: Alzheimer’s is unlikely to be driven by a single mechanism, and therapies that target different biological steps could complement existing approaches aimed at amyloid removal.
• Potential for more options: If the enzyme target is druggable, it could expand the toolbox beyond current strategies.
• Translational potential: Discovering an actionable target is a first step toward developing inhibitors, testing them in preclinical models, and eventually running clinical trials.

As with all early-stage target-hunting work, it remains essential to determine whether reducing plaques via this enzyme actually translates into meaningful cognitive benefits in patients. The story highlights the target discovery itself—without additional clinical outcomes or trial details provided in the available summary.